Search Results

Sorrento Therapeutics, Inc. announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid the billion-dollar fraud and breach of contract claims that Sorrento filed against them earlier this year.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted final approval of Sorrento’s $75 million debtor-in-possession (DIP) financing from JMB Capital Partners, in connection with Sorrento’s chapter 11 case that was filed on February 13, 2023.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.

Ewing sarcoma is a destructive sarcoma of the soft tissue and the bones, which can occur at any age with the maximum rate of incidence recorded in young adults and adolescents.

The lawsuit alleges that Soon-Shiong acquired the promising cancer treatment in order to prevent it from coming to market and challenging revenues from Celgene’s Abraxane, a drug Soon-Shiong developed.

Mateon Therapeutics, a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.

Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3 Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in

Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s